Double-blind placebo controlled clinical trial of almitrine bismesylate in patients with chronic respiratory insufficiency


The efficacy and safety of almitrine bismesylate, a new respiratory stimulant, in patients with the hypoxaemic form of chronic respiratory insufficiency caused by chronic bronchitis and emphysema has been assessed. The multicentre trial of 12 weeks duration was double-blind and placebo controlled, with individual and group comparisons. Twenty three patients… (More)
DOI: 10.1007/BF00315025


5 Figures and Tables

Slides referencing similar topics